EOLS Evolus Inc.

11.16
-0.13  -1%
Previous Close 11.29
Open 11.27
Price To Book 21.88
Market Cap 373,020,545
Shares 33,424,780
Volume 578,473
Short Ratio
Av. Daily Volume 694,534
Stock charts supplied by TradingView

NewsSee all news

  1. ALPHAEON Corporation Completes Reorganization to Simplify its Corporate Structure

    ALPHAEON Corporation ("ALPHAEON"), announced today that it has completed a reorganization to simplify its corporate structure. As a result of this reorganization the company has split into two business units, each of

  2. Evolus Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue

    Q4 2019 net revenue estimated between $18.5 and $19.5 million; increased from $13.2 million in Q3 2019 Completed Q4 2019 with over 3,500 purchasing accounts; increased from over 2,000 at end of Q3 2019

  3. Evolus to Participate in Stifel Healthcare Conference

    NEWPORT BEACH, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that

  4. Evolus Announces Pricing of Public Offering of Common Stock

    NEWPORT BEACH, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) ("Evolus") announced today the pricing of its public offering of 5,217,000 shares of its common stock at a public offering price of

  5. Evolus Announces Proposed Public Offering of Common Stock

    NEWPORT BEACH, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) ("Evolus") announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced February 1, 2019.
DWP-450
Glabellar lines

Latest News

  1. ALPHAEON Corporation Completes Reorganization to Simplify its Corporate Structure

    ALPHAEON Corporation ("ALPHAEON"), announced today that it has completed a reorganization to simplify its corporate structure. As a result of this reorganization the company has split into two business units, each of

  2. Evolus Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue

    Q4 2019 net revenue estimated between $18.5 and $19.5 million; increased from $13.2 million in Q3 2019 Completed Q4 2019 with over 3,500 purchasing accounts; increased from over 2,000 at end of Q3 2019

  3. Evolus to Participate in Stifel Healthcare Conference

    NEWPORT BEACH, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that

  4. Evolus Announces Pricing of Public Offering of Common Stock

    NEWPORT BEACH, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) ("Evolus") announced today the pricing of its public offering of 5,217,000 shares of its common stock at a public offering price of

  5. Evolus Announces Proposed Public Offering of Common Stock

    NEWPORT BEACH, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) ("Evolus") announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to

  6. Evolus Reports Third Quarter 2019 Financial Results and Provides Business Update

    Jeuveau® Generated $13.2 Million in U.S. Net Revenue in Q3 2019; up from $2.3 Million in Q2 2019 J.E.T. Enrolled Accounts Drove 90% of Q3 Revenue Jeuveau® Achieved Number Three Unit Share Position in

  7. Evolus to Report Third Quarter 2019 Financial Results and Provide a Business Update on Monday, November 4, 2019

    NEWPORT BEACH, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it

  8. Evolus Receives Approval for Nuceiva™ in the European Union

    NEWPORT BEACH, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the

  9. Evolus will Participate in Cantor Global Healthcare Conference

    NEWPORT BEACH, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that

  10. Evolus Announces Successful Completion of the Jeuveau® Experience Treatment (J.E.T) Program

    Jeuveau® Achieves Number Three Unit Share Position1 in the U.S. Within 90 Days of Launch NEWPORT BEACH, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a

  11. Evolus to Participate in Two Upcoming Investor Conferences

    NEWPORT BEACH, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that